



# असर्फी हॉस्पिटल

## सबके लिए स्वास्थ्य

AHL/AO/2025/1028

Date: November 10, 2025

To  
The Listing Department  
BSE Limited  
25th Floor, Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai – 400 001

Sub: **Outcome of the Board Meeting held on November 10, 2025 and submission of Standalone & Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2025 under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Ref: Scrip Code – 543943

Dear Sir/Madam,

Pursuant to Regulation 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”), we wish to inform you that the Board of Directors of Asarfi Hospital Limited (“the Company”), at its meeting held today, i.e., November 10, 2025, has considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2025.

The Statutory Auditors of the Company have carried out a Limited Review of the said financial results and issued their reports with an Unmodified Opinion.

Further, we wish to inform you that during the quarter, the Company has availed a term loan of ₹4.68 crore from the State Bank of India (SBI) for the purchase and installation of a new Cath Lab at Asarfi Hospital, Dhanbad, and a ₹2.00 crore fund-based Bank Guarantee (BG) limit for various empanelment’s with corporates and PSUs, as per SBI Sanction Letter No. SBI/SME-DHN/2025-26/569 dated November 7, 2025.

A copy of the Unaudited Standalone and Consolidated Financial Results, along with the Independent Auditor’s Report thereon, is enclosed herewith.

---

## Asarfi Hospital Limited

Baramuri, P.O.: B Polytechnic, Dhanbad 828 130 || CIN: L85110JH2005PLC011673  
Branch Office: Khatal Road, Dhैया, ISM, Dhanbad 826004 || [www.asarfihospital.com](http://www.asarfihospital.com)  
Phone: 7808368888, 9234302735 || Email: [info@asarfihospital.com](mailto:info@asarfihospital.com)

The Board Meeting commenced at 03:00 p.m. and concluded at 06:00 p.m.

You are requested to kindly take the above information on record.

Thanking you,  
Yours faithfully,  
For **Asarfi Hospital Limited**

*Sudipa Singh*  
(CS Sudipa Singh)



**Company Secretary & Compliance Officer**  
**Membership No.: ACS 56989**

---

## Asarfi Hospital Limited

Baramuri, P.O.: B Polytechnic, Dhanbad 828 130 || CIN: L85110JH2005PLC011673  
Branch Office: Khatal Road, Dhaiya, ISM, Dhanbad 826004 || [www.asarfihospital.com](http://www.asarfihospital.com)  
Phone: 7808368888, 9234302735 || Email: [info@asarfihospital.com](mailto:info@asarfihospital.com)

AHL/AO/2025/1030

Date: 10.11.2025

To,  
The BSE LTD.  
Listing Department  
25th Floor, Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai-400001

Dear Sir/Madam,

**Sub: Declaration regarding unaudited Reports with unmodified opinion on the Financial Statements (Standalone and Consolidated) of the Company for the Financial Half Year ended September 30, 2025**

**Ref.: Scrip Code No. 543943**

Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that **M/s R. K.Thakkar & Co**, Chartered Accountants, Statutory Auditors of the Company have issued Audit Reports with unmodified opinion on Financial Statements (Standalone and Consolidated) of the Company for the half year ended September 30, 2025,

This is for your kind information and records.

Thanking you

Yours Faithfully,  
For Asarfi Hospital Limited

*Sudipa Singh*  
(CS Sudipa Singh)



**Company Secretary & Compliance Officer**  
**Membership No.: ACS 56989**

---

## Asarfi Hospital Limited

Baramuri, P.O.: B Polytechnic, Dhanbad 828 130 || CIN: L85110JH2005PLC011673  
Branch Office: Khatal Road, Dhaiya, ISM, Dhanbad 826004 || [www.asarfihospital.com](http://www.asarfihospital.com)  
Phone: 7808368888, 9234302735 || Email: [info@asarfihospital.com](mailto:info@asarfihospital.com)

# **M/S R. K. THAKKAR & CO.**

## Chartered Accountants

Below 'Central Bank of India', Bank More, Dhanbad, 826001  
Mobile: 6203797936; email: rkthakkarco@gmail.com

### **Independent Auditor's Limited Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

Review Report to,  
The Board of Directors,  
**Asarfi Hospital Limited**  
Baramuri, Bishunpur Polytechnic,  
Dhanbad- 828130 Jharkhand

Dear Sir,


**Re:** Limited Review Report of the Unaudited Standalone Financial Results for the period from 1st July 2025 to 30<sup>th</sup> September 2025.

We have reviewed the accompanying statement of unaudited standalone financial results of **ASARFI HOSPITAL LIMITED**, year to date from 1<sup>st</sup> July 2025 to 30<sup>th</sup> September 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, ('the Regulation') as amended (the "Listing Regulations").

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our attention that cause us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with



applicable Accounting Standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of SEBI ( Listing Obligations and Disclosure Requirement) , read with the Circular, including the matter in which it is to be disclosed, or that it contains any material misstatement.

**For R K Thakkar & Co**  
**Chartered Accountants**  
**FRN: 002690C**

**Place: Dhanbad**  
**Date: 10.11.2025**  
**UDIN: 25415931BMIARM4524**

  
  
**Himanshu Kumar Dokania**  
**(Partner)**  
**Membership No. 415931**

**Asarfi Hospital Limited**  
(CIN: L85110JH2005PLC011673)  
(Address: Baramuri, Bishunpur Polytechnic, Dhanbad)  
**Standalone Unaudited Balance Sheet as at 30th September 2025**

(` in 'Lakhs)

Particulars	As on	
	30-Sep-25	31-Mar-25
	Unaudited	Audited
<b>I. EQUITY AND LIABILITIES</b>		
<b>(1) Shareholders' funds</b>		
(a) Share Capital	1,967.73	1,967.73
(b) Reserves and Surplus	6,926.05	6,176.00
<b>Total</b>	<b>8,893.78</b>	<b>8,143.73</b>
<b>(2) Non-current liabilities</b>		
(a) Long-term Borrowings	3,320.69	3,382.93
(b) Deferred Tax Liabilities (net)	344.16	337.07
(c) Other Long-term Liabilities	231.54	346.34
(d) Long-term Provisions	63.42	120.09
<b>Total</b>	<b>3,959.80</b>	<b>4,186.42</b>
<b>(3) Current liabilities</b>		
(a) Short-term Borrowings	1,464.79	1,472.80
(b) Trade Payables		
- Due to Micro and Small Enterprises	36.70	17.65
- Due to Others	1,490.54	1,285.68
(c) Other Current Liabilities	1,248.06	765.29
(d) Short-term Provisions	186.41	559.00
<b>Total</b>	<b>4,426.50</b>	<b>4,100.42</b>
<b>Total Equity and Liabilities</b>	<b>17,280.09</b>	<b>16,430.57</b>
<b>II. ASSETS</b>		
<b>(1) Non-current assets</b>		
(a) Property, Plant and Equipment and Intangible Assets		
(i) Property, Plant and Equipment	9,788.20	10,148.36
(ii) Capital Work-in-progress	391.05	193.91
(b) Non-current Investments	1.00	1.00
(c) Long term Loans and Advances	153.48	86.23
(d) Other Non-current Assets	741.77	163.88
<b>Total</b>	<b>11,075.50</b>	<b>10,593.37</b>
<b>(2) Current assets</b>		
(a) Inventories	288.26	227.67
(b) Trade Receivables	4,684.27	3,979.73
(c) Cash and cash equivalents	1,048.52	131.56
(d) Short-term Loans and Advances	178.76	87.44
(e) Other Current Assets	4.78	1,410.81
<b>Total</b>	<b>6,204.58</b>	<b>5,837.20</b>
<b>Total Assets</b>	<b>17,280.09</b>	<b>16,430.57</b>

-0.00



Place: Dhanbad  
Date: 10.11.2025

*Udai Pratap Singh*  
Udai Pratap Singh  
Managing Director  
08453794

*Madhuri Singh*  
Madhuri Singh  
Director  
6562038

*Harendra Singh*  
Harendra Singh  
CFO  
BANPS9243R

*Sudipa Singh*  
CS Sudipa Singh  
Company Secretary  
ACS No.56989



Statement of Unaudited Standalone Statement of Profit & Loss for the Quarter ended 30th September 2025

(` in 'Lakhs)

Particulars	Quarter ended			Year Ended
	30-Jun-25	30-Sep-25	30-Sep-24	31-Mar-25
	Unaudited	Unaudited	Unaudited	AHL-Audited
Revenue from Operations	3,566.41	4,484.67	3,086.06	12,056.57
Other Income	141.63	79.75	112.94	756.90
<b>Total Income</b>	<b>3,708.04</b>	<b>4,564.41</b>	<b>3,199.01</b>	<b>12,813.47</b>
<b>Expenses</b>				
Cost of Material Consumed	590.56	740.39	912.53	1,939.98
Purchases of Stock in Trade	304.64	330.79	-158.07	909.31
Change in Inventories of work in progress and finished goods	-37.82	-11.83	-20.01	-63.37
Employee Benefit Expenses	578.16	609.82	428.21	1,861.02
Finance Costs	121.88	106.53	76.20	408.09
Depreciation and Amortization Expenses	295.95	288.30	317.88	1,261.74
Other Expenses	1,427.53	1,924.56	1,243.01	5,025.24
<b>Total expenses</b>	<b>3,280.89</b>	<b>3,988.56</b>	<b>2,799.74</b>	<b>11,342.01</b>
<b>Profit/(Loss) before Exceptional and Extraordinary Item and Tax</b>	<b>427.14</b>	<b>575.85</b>	<b>399.26</b>	<b>1,471.46</b>
Exceptional Item				
<b>Profit/(Loss) before Extraordinary Item and Tax</b>	<b>427.14</b>	<b>575.85</b>	<b>399.26</b>	<b>1,471.46</b>
Extraordinary Item				
<b>Profit/(Loss) before Tax</b>	<b>427.14</b>	<b>575.85</b>	<b>399.26</b>	<b>1,471.46</b>
Tax Expenses				
- Current Tax	107.50	138.35	-	307.56
- Deferred Tax	-	7.09	108.42	65.46
-Prior Period Taxes	-	-	0.46	0.46
<b>Profit/(Loss) after Tax</b>	<b>319.64</b>	<b>430.41</b>	<b>290.38</b>	<b>1,097.97</b>
<b>Profit/(Loss) for the period (before Minority interest adjustment)</b>	<b>319.64</b>	<b>430.41</b>	<b>290.38</b>	<b>1,097.97</b>
Less: Minority interest in (Profit)/losses				
<b>Profit/(Loss) for the period (after Minority interest adjustment)</b>	<b>319.64</b>	<b>430.41</b>	<b>290.38</b>	<b>1,097.97</b>
Earnings Per Share (Face Value per Share Rs.10 each)				
-Basic (In Rs)	1.62	2.19	1.48	5.58
-Diluted (In Rs)	1.62	2.19	1.48	5.58

1 The above results have been reviewed by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on November 10, 2025

2 The Statutory Auditor of the company carried out the limited Review of above result as per Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3 As per Accounting Standard - 17 on "Segment Reporting" (AS 17), the company has only one reportable segment viz Hospital.

As per MCA notification dated 16th February 2015 companies whose shares are listed in SME exchange as referred to Chapter IX of SEBI (Issue of Capital and Disclosure Requirements)

4 Regulation, 2018 are exempted from compulsory requirement of adoption of IND AS.

5 Earning per Share are calculated on weighted average of the share capital outstanding during the year/ half year/ period EPS is not annualised.

6 The figures of the second quarter in each of the financial years are the balancing figures between unaudited figures in respect of the half year end and the published year to date figures upto the end of the first quarter of respective financial year.

7 Previous year's/ period's have been regrouped/ rearranged wherever necessary.



Place: Dhanbad  
Date: 10.11.2025

*Udal Pratap Singh*  
Udal Pratap Singh  
Managing Director  
08453794

*Madhuri Singh*  
Madhuri Singh  
Director  
6562038



on behalf of the Board  
Asarfi Hospital Limited

*Harendra Singh*  
Harendra Singh  
CFO  
BANPS9243R

*Sudipa Singh*  
CS Sudipa Singh  
Company Secretary  
ACS No.56989

**Asarfi Hospital Limited**

(CIN: L85110JH2005PLC011673)

(Address: Baramuri, Bishunpur Polytechnic, Dhanbad)

**Unaudited Cash Flow Statement for the Half Year ended 30th September 2025**

(` in 'Lakhs)

Particulars	Half Year	Year ended
	30-Sep-25	31-Mar-25
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit after tax	750.05	1,097.97
Profit/(loss) from Discontinuing Operation (after tax)	-	-
Depreciation and Amortisation Expense	584.25	1,261.74
Provision for tax	252.94	373.49
Loss/(Gain) on Sale / Discard of Assets (Net)	-	-39.80
Non operating Income	-	-323.82
Non operating Expenses	-	30.99
Interest Income	-51.24	-125.68
Finance Costs	222.13	408.09
<b>Operating Profit before working capital changes</b>	<b>1,758.13</b>	<b>2,682.98</b>
<b>Adjustment for:</b>		
Inventories	-60.59	-47.68
Trade Receivables	-704.55	-1,554.02
Loans and Advances	12.70	256.55
Other Current Assets	9.30	-8.27
Other Non current Assets	15.92	-
Trade Payables	223.91	-1,193.69
Other Current Liabilities	463.25	-106.38
Long term Liabilities	-114.80	-340.74
Short-term Provisions	-372.59	212.79
Long-term Provisions	-56.67	22.22
Cash (Used in)/Generated from Operations	1,174.02	-76.23
Tax paid(Net)	245.85	308.03
<b>Net Cash (Used in)/Generated from Operating Activities</b>	<b>928.17</b>	<b>-384.26</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of Property, Plant and Equipment & CWIP	-505.74	-968.85
Sale of Property, Plant and Equipment	-	129.15
Decrease /Increase in Capital WIP	-	-193.91
Loans and Advances given	-67.25	-72.64
Proceeds from Loans and Advances	-	-
Investment/Reclassification in/to Term Deposits	6.23	-
Maturity of Term Deposits	-	183.32
Movement in other non current assets	-	7.09
Interest received	32.85	125.68
Dividend received	-	-
<b>Net Cash (Used in)/Generated from Investing Activities</b>	<b>-533.90</b>	<b>-790.16</b>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from Long Term Borrowings	267.77	2,203.80
Repayment of Long Term Borrowings	-330.01	-467.73
Proceeds from Short Term Borrowings	32.23	13.27
Repayment of Short Term Borrowings	-40.24	-84.83
Interest Paid	-222.13	-407.63
<b>Net Cash (Used in)/Generated from Financing Activities</b>	<b>-292.38</b>	<b>1,256.88</b>
<b>Net Increase/(Decrease) in Cash and Cash Equivalents</b>	<b>101.89</b>	<b>82.46</b>
Opening Balance of Cash and Cash Equivalents	131.56	49.10
Exchange difference of Foreign Currency Cash and Cash equivalents	-	-
<b>Closing Balance of Cash and Cash Equivalents</b>	<b>233.44</b>	<b>131.56</b>

Components of cash and cash equivalents	30-September-2025	31-March-2025
Cash on hand	156.10	105.64
Cheques, drafts on hand	-	-
Balances with banks in current accounts	44.77	25.91
Bank Deposit having maturity of less than 3 months	32.58	-
Others	-	-
<b>Cash and cash equivalents as per Cash Flow Statement</b>	<b>233.44</b>	<b>131.56</b>
<b>Other Bank Balance</b>		
Bank Deposit having maturity of greater than 3 months and less than 12 months	815.08	-
Bank Deposit having maturity of greater than 12 months	-	-
Less: Deposits reclassified to other non current assets	-	-
<b>Cash and bank balance as per Balance Sheet</b>	<b>1,048.52</b>	<b>131.56</b>

**Note:**

1. The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard 3 (AS-3), "Cash Flow Statements".

**2. Reclassification of Fixed Deposit Balance**

Fixed deposits with original maturity of more than three months but less than twelve months were previously presented under Other Current Assets in the audited financial statements for the year ended 31 March 2025. For the purpose of the half-yearly financial results ended 30 September 2025, these have been reclassified under "Other Bank Balances" (forming part of Cash and Cash Equivalents) in accordance with Schedule III and AS 3. The reclassification has no impact on the total assets, liabilities or profit of the Company. Previous period figures have not been restated.



Place: Dhanbad  
Date: 10.11.2025

*Uday Pratap Singh*  
Managing Director  
08453794

*Madhuri Singh*  
Director  
6562038



*Harendra Singh*  
CFO  
BANPS9243R

*Sudipa Singh*  
CS Sudipa Singh  
Company Secretary  
ACS No.56989

# M/S R. K. THAKKAR & CO.

## Chartered Accountants

Below 'Central Bank of India', Bank More, Dhanbad, 826001  
Mobile: 6203797936; email: rkthakkarco@gmail.com

**Independent Auditor's Limited Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

Review Report to,  
The Board of Directors,  
**Asarfi Hospital Limited**  
Baramuri, Bishunpur Polytechnic,  
Dhanbad- 828130 Jharkhand

Dear Sir,

**Re:** Limited Review Report of the Unaudited Consolidated Financial Results for the period from 1st July 2025 to 30<sup>th</sup> September 2025

We have reviewed the accompanying statement of unaudited consolidated financial results of **ASARFI HOSPITAL LIMITED**, which include its subsidiary namely *Asarfi Educational Foundation*, year to date from 1st July 2025 to 30<sup>th</sup> September 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, ('the Regulation') as amended (the "Listing Regulations").

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that cause us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with applicable Accounting Standards specified under Section 133 of the Companies Act, 2013



as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of SEBI ( Listing Obligations and Disclosure Requirement) , read with the Circular, including the matter in which it is to be disclosed, or that it contains any material misstatement.

**For R K Thakkar & Co**  
**Chartered Accountants**  
**FRN: 002690C**

**Place: Dhanbad**  
**Date: 10.11.2025**  
**UDIN: 25415931BMIARN6323**

  
**Himanshu Kumar Dokania**  
**(Partner)**  
**Membership No. 415931**



**Asarfi Hospital Limited**

(CIN: L85110JH2005PLC011673)

(Address: Baramuri, Bishunpur Polytechnic, Dhanbad)

**Unaudited Consolidated Balance Sheet as at 30th September 2025**

(` in 'Lakhs)

Particulars	As at	
	30-Sep-25	31-Mar-25
	Unaudited	Audited
<b>I. EQUITY AND LIABILITIES</b>		
<b>(1) Shareholders' funds</b>		
(a) Share Capital	1,967.73	1,967.73
(b) Reserves and Surplus	6,862.44	6,130.59
<b>Total</b>	<b>8,830.17</b>	<b>8,098.32</b>
<b>(2) Non-current liabilities</b>		
(a) Long-term Borrowings	3,320.69	3,382.93
(b) Deferred Tax Liabilities (net)	344.16	337.07
(c) Other Long-term Liabilities	231.54	346.34
(d) Long-term Provisions	63.42	120.09
<b>Total</b>	<b>3,959.80</b>	<b>4,186.42</b>
<b>(3) Current liabilities</b>		
(a) Short-term Borrowings	1,464.79	1,472.80
(b) Trade Payables	-	-
- Due to Micro and Small Enterprises	36.70	17.65
- Due to Others	1,490.82	1,285.92
(c) Other Current Liabilities	1,252.32	767.19
(d) Short-term Provisions	186.98	560.36
<b>Total</b>	<b>4,431.61</b>	<b>4,103.92</b>
<b>Total Equity and Liabilities</b>	<b>17,221.58</b>	<b>16,388.67</b>
<b>II. ASSETS</b>		
<b>(1) Non-current assets</b>		
(a) Property, Plant and Equipment and Intangible Assets		
(i) Property, Plant and Equipment	9,800.56	10,164.44
(ii) Capital Work-in-progress	391.05	193.91
(b) Non-current Investments	-	-
(c) Long term Loans and Advances	-	-
(d) Other Non-current Assets	808.77	181.88
<b>Total</b>	<b>11,000.38</b>	<b>10,540.23</b>
<b>(2) Current assets</b>		
(a) Inventories	288.26	227.67
(b) Trade Receivables	4,686.18	3,979.73
(c) Cash and cash equivalents	1,062.55	142.63
(d) Short-term Loans and Advances	179.43	87.61
(e) Other Current Assets	4.78	1,410.81
<b>Total</b>	<b>6,221.20</b>	<b>5,848.44</b>
<b>Total Assets</b>	<b>17,221.58</b>	<b>16,388.67</b>



Place: Dhanbad  
Date: 10.11.2025

*Udai Pratap Singh*  
Udai Pratap Singh  
Managing Director  
08453794

*माधुरी सिंह*  
Madhuri Singh  
Director  
6562038



*Harendera Singh*  
Harendera Singh  
CFO  
BANPS9243R

*Sudipa Singh*  
CS Sudipa Singh  
Company Secretary  
ACS No.56989

**Asarfi Hospital Limited**

(CIN: L85110JH2005PLC011673)

(Address: Baramuri, Bishunpur Polytechnic, Dhanbad)

**Statement of Unaudited Consolidated Profit & Loss Statement for the Quarter ended 30th September 2025**

(` in 'Lakhs)

Particulars	Quarter ended	Quarter Ended	Quarter Ended	Year ended
	30-Jun-25	30-Sep-25	30-Sep-24	31-Mar-25
	Unaudited	Unaudited	Unaudited	Audited
Revenue from Operations	3,568.11	4,489.06	3,086.06	12,056.57
Other Income	141.63	75.92	112.94	751.99
<b>Total Income</b>	<b>3,709.74</b>	<b>4,564.98</b>	<b>3,199.01</b>	<b>12,808.56</b>
<b>Expenses</b>				
Cost of Material Consumed	590.56	740.39	912.53	1,939.98
Purchases of Stock in Trade	304.64	330.79	(158.07)	909.31
Change in Inventories of work in progress and finished goods	-37.82	(11.83)	(20.01)	(63.37)
Employee Benefit Expenses	580.33	612.31	428.21	1,863.23
Finance Costs	121.88	106.53	76.20	408.09
Depreciation and Amortization Expenses	299.13	291.28	319.19	1,267.60
Other Expenses	1,431.41	1,930.34	1,247.10	5,052.61
<b>Total expenses</b>	<b>3,290.13</b>	<b>3,999.81</b>	<b>2,805.16</b>	<b>11,377.45</b>
<b>Profit/(Loss) before Exceptional and Extraordinary Item and Tax</b>	<b>419.61</b>	<b>565.17</b>	<b>393.85</b>	<b>1,431.11</b>
Exceptional Item				
<b>Profit/(Loss) before Extraordinary Item and Tax</b>	<b>419.61</b>	<b>565.17</b>	<b>393.85</b>	<b>1,431.11</b>
Extraordinary Item				
<b>Profit/(Loss) before Tax</b>	<b>419.61</b>	<b>565.17</b>	<b>393.85</b>	<b>1,431.11</b>
Tax Expenses				
- Current Tax	107.50	138.35	-	307.56
- Deferred Tax	-	7.09	108.42	65.46
-Prior Period Taxes	-	-	0.46	0.46
<b>Profit/(Loss) after Tax</b>	<b>312.11</b>	<b>419.74</b>	<b>284.97</b>	<b>1,057.62</b>
<b>Profit/(Loss) for the period (before Minority interest adjustment)</b>	<b>312.11</b>	<b>419.74</b>	<b>284.97</b>	<b>1,057.62</b>
Less: Minority interest in (Profit)/losses				
<b>Profit/(Loss) for the period (after Minority interest adjustment)</b>	<b>312.11</b>	<b>419.74</b>	<b>284.97</b>	<b>1,057.62</b>
Earnings Per Share (Face Value per Share Rs.10 each)				
-Basic (In Rs)	1.59	2.13	1.45	5.37
-Diluted (In Rs)	1.59	2.13	1.45	5.37

1 The above results have been reviewed by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on November 10, 2025.

2 The Statutory Auditor of the company carried out the limited Review of above result as per Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3 As per Accounting Standard - 17 on "Segment Reporting" (AS 17), the company has only one reportable segment viz Hospital.

4 As per MCA notification dated 16th February 2015 companies whose shares are listed in SME exchange as referred to Chapter IX of SEBI (Issue of Capital and Disclosure Requirements)

4 Regulation, 2018 are exempted from compulsory requirement of adoption of IND AS.

5 Earning per Share are calculated on weighted average of the share capital outstanding during the year/ half year/ period EPS is not annualised.

6 The figures of the second quarter in each of the financial years are the balancing figures between unaudited figures in respect of the half year end and the published year to date figures upto the end of the first quarter of respective financial year.


7 Previous year's/ period's have been regrouped/ rearranged wherever necessary.



Place: Dhanbad  
Date: 10.11.2025

  
Udai Pratap Singh  
Managing Director  
084537947

  
Mahendra Singh  
Director  
6562038

  
Harendra Singh  
CFO  
BANPS9243R

  
CS Sudipa Singh  
Company Secretary  
ACS No.56989



For and on behalf of the Board  
Asarfi Hospital Limited

**Unaudited Consolidated Cash Flow Statement for the Half Year ended 30th September 2025**

(₹ in 'Lakhs)

Particulars	Half Year ended	Year Ended
	30-Sep-25	31-Mar-25
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit after tax	731.84	1,057.62
Profit/(loss) from Discontinuing Operation (after tax)	-	-
Depreciation and Amortisation Expense	590.41	1,267.60
Provision for tax	252.94	373.49
Loss/(Gain) on Sale / Discard of Assets (Net)	-	(39.80)
Non operating Income	-	(323.82)
Non operating Expenses	-	30.99
Interest Income	(47.42)	(120.77)
Finance Costs	222.13	408.09
Operating Profit before working capital changes	1,749.91	2,653.40
<b>Adjustment for:</b>		
Inventories	(60.59)	(47.68)
Trade Receivables	(706.46)	(1,554.02)
Loans and Advances	12.70	256.42
Other Current Assets	9.30	(8.27)
Other Non current Assets	15.92	(18.00)
Trade Payables	223.95	(1,199.87)
Other Current Liabilities	465.61	(104.48)
Long term Liabilities	(114.80)	(340.74)
Short-term Provisions	(373.38)	214.05
Long-term Provisions	(56.67)	22.22
	-	-
Cash (Used in)/Generated from Operations	1,165.49	(126.95)
Tax paid(Net)	245.85	308.03
<b>Net Cash (Used in)/Generated from Operating Activities</b>	<b>919.64</b>	<b>(434.98)</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of Property, Plant and Equipment & CWIP	(508.17)	(984.81)
Sale of Property, Plant and Equipment	-	129.15
Decrease /Increase in Capital WIP	-	(193.91)
Loans and Advances given	(0.50)	-
Investment/Reclassification in/to Term Deposits	6.23	-
Maturity of Term Deposits	-	183.32
Movement in other non current assets	(49.00)	7.09
Interest received	29.03	120.77
Dividend received	-	-
<b>Net Cash (Used in)/Generated from Investing Activities</b>	<b>(522.42)</b>	<b>(738.39)</b>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from Long Term Borrowings	267.77	2,203.80
Repayment of Long Term Borrowings	(330.01)	(467.73)
Proceeds from Short Term Borrowings	32.23	13.27
Repayment of Short Term Borrowings	(40.24)	(84.83)
Interest Paid	(222.13)	(407.63)
<b>Net Cash (Used in)/Generated from Financing Activities</b>	<b>(292.38)</b>	<b>1,256.88</b>
<b>Net Increase/(Decrease) in Cash and Cash Equivalents</b>	<b>104.85</b>	<b>83.51</b>
Opening Balance of Cash and Cash Equivalents	142.63	59.12
Exchange difference of Foreign Currency Cash and Cash equivalents	-	-
<b>Closing Balance of Cash and Cash Equivalents</b>	<b>247.47</b>	<b>142.63</b>

Components of cash and cash equivalents	30-September-2025	31-March-2025
Cash on hand	157.93	105.78
Cheques, drafts on hand	-	-
Balances with banks in current accounts	56.96	36.84
Bank Deposit having maturity of less than 3 months	32.58	-
Others	-	-
<b>Cash and cash equivalents as per Cash Flow Statement</b>	<b>247.47</b>	<b>142.63</b>
<b>Other Bank Balance</b>		
Bank Deposit having maturity of greater than 3 months and less than 12 months	815.08	-
Bank Deposit having maturity of greater than 12 months	-	-
Less: Deposits reclassified to other non current assets	-	-
<b>Cash and bank balance as per Balance Sheet</b>	<b>1,062.55</b>	<b>142.63</b>

**Note:**

1. The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard 3 (AS-3), "Cash Flow Statements".

**2. Reclassification of Fixed Deposit Balances**

Fixed deposits with original maturity of more than three months but less than twelve months were previously presented under Other Current Assets in the audited financial statements for the year ended 31 March 2025. For the purpose of the half-yearly financial results ended 30 September 2025, these have been reclassified under "Other Bank Balances" (forming part of Cash and Cash Equivalents) in accordance with Schedule III and AS 3. The reclassification has no impact on the total assets, liabilities or profit of the Company. Previous period figures have not been restated.








Uday Pratap Singh      Madhuri Singh      Harindra Singh      CS Sudipa Singh  
 Managing Director      Director      CFO      Company Secretary  
 08453794      6562038      BANPS9243R      ACS No.56989